Zhang J, Boesjes CM, Loman L, Kamphuis E, et al. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry. J Am Acad Dermatol 2024 Apr 21:S0190-9622(24)00641.
PMID: 38653344